Daniel Alcalá-López

Computing the Social Brain Connectome Across Systems and States

Daniel Alcalá-López, Jonathan Smallwood, Elizabeth Jefferies et al. · Cerebral Cortex · 2017 · 185 citations

Neuropsychology, Brain Function, Brain Mechanism +18

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

Antonio Llombart‐Cussac, Catherine Harper‐Wynne, Antonia Perelló et al. · Journal of Clinical Oncology · 2023 · 69 citations

Breast Oncology, Pharmacotherapy, Pre-clinical Pharmacology +17

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego et al. · The Lancet · 2024 · 69 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +4

The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós et al. · Med · 2024 · 33 citations

Breast Oncology, Medicine, Leptomeningeal Carcinomatosis +6

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

Marta Vaz Batista, José Manuel Pérez-García, Patricia Cortez et al. · ESMO Open · 2024 · 26 citations · Full text

Breast Oncology, Oncology, Breast Cancer +5